Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 5/20 | 0.34 |
| ▸ | NPC1 | O15118 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | SCN4A | P35499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL637899 | 0.65 | ALDH1A1 (0.36) | TDO2ALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6829225 | 0.64 | ALDH1A1 (0.40) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1 | |
| SCHEMBL136631 | 0.62 | NOTUM (0.61) | TDO2ALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5047733 | 0.59 | ALDH1A1 (0.47) | ALDH1A1RAB9ANPC1MAPK1NOTUM | |
| SCHEMBL852224 | 0.58 | ALDH1A1 (0.67) | ALDH1A1RAB9ANPC1MAPK1NOTUM | |
| SCHEMBL532969 | 0.58 | ALDH1A1 (0.67) | ALDH1A1RAB9ANPC1MAPK1NOTUM | |
| SCHEMBL532970 | 0.58 | ALDH1A1 (0.67) | ALDH1A1RAB9ANPC1MAPK1NOTUM | |
| Biphenyl SCHEMBL164 | 0.57 | ALDH1A1 (1.00) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1 | |
| Biphenyl SCHEMBL2548048 | 0.57 | ALDH1A1 (1.00) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1 | |
| Biphenyl SCHEMBL1358618 | 0.57 | ALDH1A1 (1.00) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48841-E1 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-07 | — | — | US | claimed |
| EP-2491038-B1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-06 | — | — | EP | claimed |
| US-8680275-B2 | Fused heterocyclic compounds as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-25 | — | — | US | claimed |
| US-8653263-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA (BE) | 2014-02-18 | — | — | US | claimed |
| EP-2491034-B1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-18 | — | — | EP | claimed |
| EP-2491034-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2012-08-29 | — | — | EP | claimed |
| EP-2491038-A1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2012-08-29 | — | — | EP | claimed |
| US-20120208812-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-16 | — | — | US | claimed |
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN RESEARCH NV (BE) | 2012-08-09 | — | — | US | claimed |
| WO-2011050198-A1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | claimed |
| WO-2011050200-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | claimed |
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | claimed |
| EP-2099753-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-09-16 | — | — | EP | claimed |
| EP-1939180-A1 | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | claimed |
| WO-2008074413-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS FOR THE STIMULATION OF THE EXPRESSION OF ENDOTHELIAL NO SYNTHASE | SANOFI-AVENTIS (FR) | 2008-06-26 | — | — | WO | claimed |
| EP-1003736-B1 | SUBSTITUTED 4-BENZOYL-PYRAZOLES | BASF AG (DE) | 2006-04-12 | — | — | EP | claimed |
| US-6559100-B1 | Herbicidal activity of the substituted 2-benzoylcyclohexane-1,3-diones of the formula I was demonstrated by greenhouse experiments | BASF AKTIENGESELLSCHAFT (DE) | 2003-05-06 | — | — | US | claimed |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-04 | — | — | US | disclosed |
| US-6207618-B1 | Heterocyclic substituted 4-benzoyl-pyrazole as herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| US-6156702-A | Substituted 4-benzoylpyrazoles | BASF AKTIENGESELLSCHAFT (DE) | 2000-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208812-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | TDO2 1454/4885ALDH1A1 3132/4885RAB9A 2680/4885 |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | TDO2 1454/4885ALDH1A1 3132/4885RAB9A 2680/4885 |
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | TDO2 1572/4885ALDH1A1 2475/4885RAB9A 1926/4885 |
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | NOS3, PTGIS, NOS1 | TDO2 3292/4885ALDH1A1 2657/4885RAB9A 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.